Background: Hepatitis   C   is   a   worldwide   problem   with   a   prevalence estimated to be 3 % according to the World Health Organization (WHO) about 130-150 million people worldwide are chronically infected with hepatitis C virus (HCV).  Egypt has the highest prevalence of HCV estimated to be 7.3% with predominance of genotype 4. Direct -acting  antiviral  agents  (DAAs)  are  highly effective and  well tolerated  in patients with  chronic  hepatitis  C virus infection,  including  those  with  compensated cirrhosis. The availability of antiviral agents, which can be administered in short, interferon (IFN)‐free regimens, has improved the management of patients with HCV infection dramatically. Clinical studies have demonstrated rates of sustained virologic response (SVR) of over 90% with these regimens, even in patients with compensated cirrhosis. Aim: The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational prospective study was conducted on 100 patients with compensated cirrhosis treated in 2017, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensation. Results: Most patients were males (60%), the mean age was 57.3±6.1years. All participants were Child-Pugh A class at the start of the treatment.  SVR 12 was achieved in all patients (100%). Eight  patients  suffered  clinical  decompensation,  three( 3.3%) of  them  changed to Child B and five (5.5%) patients  changed to Child C. The incidence of de novo hepatocellular carcinoma during the follow-up was (4 %). There was a significant improvement in the mean platelets count, AST, ALT (P < 0.001) after treatment and the mean albumin level decreased but still in the normal range. Conclusion: Treatment with Direct-acting antiviral was assosciated with high rates of SVR, but not associated in the short term with a decrease in the development of hepatic decompensation or hepatocellular carcinoma compared to what it was reported for untreated compensated cirrhotic patients.